Quick trade to above 2p - |
Eva Perone - I fear your destiny is less pharma. More the cappuccino maker. |
Me too eva... hope you still have hammersmith xxx |
Booked decent loss
Heartbreaking but I'm now done with IMM.
Onto Destiny Pharma now |
You are maybe confusing me with Arlington Chetwynd Talbot - we are different people. |
ACT ru the reAlOne orA clone?? |
You may be right, but you seem to say that about every share. |
Well another placing coming? |
Timberrrrrrrrr!Lemmings and mushrooms only! |
What is imm actually doing now? |
 Interesting development in lupus treatment:
CAR T cell therapy could reach beyond cancer
by Perelman School of Medicine at the University of Pennsylvania
Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this development in a commentary published today in Cell.
[ ... ]
The commentary from June and Baker comes in response to the first significant clinical report of success from these efforts: a paper in Nature Medicine from German researchers on the use of CAR T therapy against the autoimmune disease lupus (systemic lupus erythematosus).
Researchers say lupus is an obvious choice for CAR T therapy because it too is driven by B cells, and thus experimental CAR T therapies against it can employ existing anti-B-cell designs. B cells are the immune system's antibody-producing cells, and, in lupus, B cells arise that attack the patient's own organs and tissues.
In the German study, the patients—five young adults—did not benefit from standard lupus treatments. Yet, all went into remission, and were able to stop taking their lupus drugs within three months of a single, relatively small dose of CAR T therapy, which essentially removed their existing B cells. (Cancer patients subsequently require infusions of purified human antibodies from healthy volunteers, to maintain some antibody immunity.)
Even more remarkably, all the patients remained in remission during the follow-up period of up to a year, and unlike cancer patients, the lupus patients experienced the return of their B cells, which are naturally replenished from blood stem cells in bone marrow.
[ ... ] |
Just spotted that stanford have issued an updated research
note this morning can be seen on their website,also on research tree
if you use that. |
Its true he did say that in interview. Now we know why all those warrants price reduced to 5p, they expected this but mislead investors. |
Good point neo! It’s shocking really… |
He mislead us the ceo he said phase 3 was already agreed to last year.. |
Nobby - I agree TM has told a lot less than the whole truth. Now find me an AIM CEO of whom that could not be said. Even the saints and sirs, as you know, can bend or avoid the facts to suit their own purposes :¬(
All that said, it will be interesting to see the outcome of the trials, and finally find out for sure whether there is a significant dose-related effect. |
OCTP are the place to be, with Phase 1 starting in January and results due in April. Easy 10x bagger. |
I have been critical of Muller in the past. The science was contradictory and muddled and she completely changed her mind about the site of action. This was a critical part of determining the necessary drug level in vivo to see activity so directly lead to the current issue IMHO.
So SN yes I agree with you to some extent although there is no doubt McCarthy has been economical with the truth all the way through. I still remember him saying in an interview after the phase III results that the trial showed Lupuzor worked. It was a gobsmacking statement because it was the exact opposite of the truth! |
Easy to criticise McCarthy, but if the prize-winning scientist at the centre of all this had done her job as well as he's done his, they wouldn't be in anything like the mess they're currently in. Just saying. |
I would say "precise but vague" is what the company are saying; and what does the distribution agreement mean? IMM aren't in to that market are they? Anyhow its clear Avion saw an opportunity to get more than the US rights, whatever it is they wanted. Maybe the good news is that Avion see a future for Lupuzor but at what cost to IMM? Anyhow its impossible to determine precisely what the new test is and speculation is pointless until the cloud clears.
Whoever is pulling the strings at the FDA they certainly got it delayed, unlike Covid stuff - seems some stuff gets tested to detail and other stuff is waved through. Perhaps IMM should have sold rights to GSK or some other deal with a big pharma! |
Oh dear not so good then?
I wouldn't touch anything Tim Mc was involved in after AZM debacle. I thought maybe he had turned a corner.... |
>> waterloo
Yes why would Avion let a company with no sales experience market their drugs. It makes no sense…. |
As expected, oh dear. As for the distribution agreement...... really. |
RNS sounds reasonably positive? |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
